KURA - Kura Oncology, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
17.26
+0.54 (+3.23%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close16.72
Open16.68
Bid0.00 x 800
Ask17.74 x 1300
Day's Range16.51 - 17.46
52 Week Range6.35 - 21.42
Volume643,554
Avg. Volume681,964
Market Cap964.863M
Beta (5Y Monthly)2.28
PE Ratio (TTM)N/A
EPS (TTM)-1.56
Earnings DateMay 04, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.38
  • GlobeNewswire

    Kura Oncology Reports Overall Survival Data from Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Squamous Cell Carcinoma

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced updated clinical outcome data from its RUN-HN study, a Phase 2 open-label, single-arm trial of tipifarnib in patients with HRAS mutant head and neck squamous cell carcinoma (HNSCC) whose disease had progressed after prior therapy. A copy of the presentation is available on Kura's website at www.kuraoncology.com/pipeline/publications.

  • GlobeNewswire

    Kura Oncology Announces Three Abstracts Accepted for Presentation at ASCO20 Virtual Scientific Program

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that three abstracts highlighting its drug candidate tipifarnib have been accepted for presentation at the upcoming American Society of Clinical Oncology (ASCO) Virtual Scientific Program, to be held May 29-31, 2020. “We are pleased to announce the presentation of three clinical abstracts for tipifarnib, including an oral presentation highlighting single-agent activity in multiple solid tumors with HRAS mutations,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology.

  • Thomson Reuters StreetEvents

    Edited Transcript of KURA earnings conference call or presentation 4-May-20 8:30pm GMT

    Q1 2020 Kura Oncology Inc Earnings Call

  • GlobeNewswire

    Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares

    SAN DIEGO, May 08, 2020 -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the.

  • GlobeNewswire

    Kura Oncology to Present at BofA Securities Virtual Health Care Conference 2020

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation at the BofA Securities Virtual Healthcare Conference 2020. Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of two wholly owned small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment.

  • GlobeNewswire

    Kura Oncology Announces Pricing of $125 Million Public Offering of Common Stock

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the pricing of an underwritten public offering of 9,100,000 shares of its common stock at a price to the public of $13.75 per share. The gross proceeds to Kura from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Kura, are expected to be approximately $125.1 million. The offering is expected to close on or about May 8, 2020, subject to customary closing conditions.

  • GlobeNewswire

    Kura Oncology Announces Commencement of Public Offering of Common Stock

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock. In connection with the offering, Kura expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. SVB Leerink, Cowen and Credit Suisse are acting as joint bookrunning managers in the offering.

  • Kura Oncology, Inc. (KURA) Q1 2020 Earnings Call Transcript
    Motley Fool

    Kura Oncology, Inc. (KURA) Q1 2020 Earnings Call Transcript

    Joining me on the call from Kura are Dr. Troy Wilson, our President and Chief Executive Officer and Dr. Marc Grasso, our Chief Financial Officer and Chief Business Officer. Jim Basta, our Chief Legal Officer; Kirsten Flowers, our Chief Commercial Officer; Kathy Ford, our Chief Operating Officer; and Dr. Bridget Martell, our acting Chief Medical Officer are also with us and available to answer questions. Before I turn the call over to Dr. Wilson, I would like to remind you that today's call will include forward-looking statements based on current expectations.

  • GlobeNewswire

    Kura Oncology Reports First Quarter 2020 Financial Results

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported first quarter 2020 financial results and provided a corporate update. “We recently completed a strategic review of our portfolio with the goal of prioritizing programs that have the highest potential to create value,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology.

  • GlobeNewswire

    Kura Oncology to Report First Quarter 2020 Financial Results

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that it will report first quarter 2020 financial results after the close of U.S. financial markets on Monday, May 4, 2020. Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 877-516-3514 for domestic callers and 281-973-6129 for international callers and entering the conference code: 2085246.

  • Why Kura Oncology Is Skyrocketing Today
    Motley Fool

    Why Kura Oncology Is Skyrocketing Today

    Shares of Kura Oncology (NASDAQ: KURA) -- a clinical-stage biopharmaceutical company that focuses on developing cancer treatments -- were up by 42.6% as of 1:49 p.m. EDT on Tuesday. The company did not report any news, but its stock is probably riding the wave of Syndax Pharmaceuticals (NASDAQ: SNDX), another clinical-stage drugmaker whose shares are up by more than 50% as a result of positive data from a phase 1 clinical trial. Syndax released data from a phase 1 clinical trial for SNDX-5613 on Monday, saying that the data provided "the first clinical evidence that disrupting the interaction between menin and MLL1 with our potent and selective inhibitor, SNDX-5613, can induce response in patients with genetically defined acute leukemias."

  • Thomson Reuters StreetEvents

    Edited Transcript of KURA earnings conference call or presentation 25-Feb-20 9:30pm GMT

    Q4 2019 Kura Oncology Inc Earnings Call

  • GlobeNewswire

    Kura Oncology Receives Fast Track Designation for Tipifarnib in T-Cell Lymphomas

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company’s lead drug candidate, tipifarnib, for the treatment of adult patients with relapsed or refractory angioimmunoblastic T-cell lymphoma (AITL), follicular T-cell lymphoma (FTCL) and nodal peripheral T-cell lymphoma with T follicular helper (TFH) phenotype. “This important designation from the FDA comes just two months after tipifarnib was awarded Fast Track for the treatment of patients with HRAS mutant head and neck squamous cell carcinomas (HNSCC),” said Bridget Martell, M.A., M.D., Acting Chief Medical Officer of Kura Oncology.

  • GlobeNewswire

    Kura Oncology Reports Fourth Quarter and Full Year 2019 Financial Results

    – Registration-directed trial of tipifarnib in HRAS mutant head and neck squamous cell carcinomas anticipated to complete enrollment in first quarter of 2021 – – Company.

  • GlobeNewswire

    Kura Oncology to Participate in Three Upcoming Investor Conferences

    SAN DIEGO, Feb. 19, 2020 -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment.

  • GlobeNewswire

    Kura Oncology to Report Fourth Quarter and Full Year 2019 Financial Results

    SAN DIEGO, Feb. 18, 2020 -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment.

  • GlobeNewswire

    Kura Oncology Announces Transition of Chief Medical Officer

    – Dr. Antonio Gualberto to step down after enabling multiple registrational strategies for tipifarnib, positioning program for success – – Clinical development, regulatory and.

  • GlobeNewswire

    Kura Oncology to Present at J.P. Morgan Healthcare Conference

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced its participation at the 38th Annual J.P. Morgan Healthcare Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to present an overview of the company on Thursday, January 16, 2020 at 10:00 a.m. PT / 1:00 p.m. ET, followed by a Q&A session at 10:30 a.m. PT / 1:30 p.m. ET. Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer.

  • GlobeNewswire

    Kura Oncology Appoints Kirsten Flowers as Chief Commercial Officer

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced the appointment of Kirsten Flowers as Chief Commercial Officer. Ms. Flowers joins Kura most recently from Array Biopharma, where she served as head of commercial operations until the completion of its $11.4 billion acquisition by Pfizer in July 2019. “Kirsten is a world-class leader in building successful commercial organizations and launching precision medicines for the treatment of cancer,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology.

  • GlobeNewswire

    Kura Oncology Receives Fast Track Designation for Tipifarnib in HRAS Mutant HNSCC and Provides Enrollment Guidance for AIM-HN Trial

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company’s lead drug candidate, tipifarnib, for the treatment of patients with HRAS mutant head and neck squamous cell carcinomas (HNSCC) after progression on platinum therapy. “We are very encouraged by our growing body of clinical data for tipifarnib in HRAS mutant HNSCC and believe that the FDA’s Fast Track designation puts us one step closer to delivering a precision medicine treatment for patients with this devastating disease,” said Antonio Gualberto, M.D., Ph.D., Head of Development and Chief Medical Officer of Kura Oncology.

  • GlobeNewswire

    Kura Oncology Reports Clinical and Regulatory Updates for Tipifarnib in Angioimmunoblastic T-Cell Lymphoma

    – Tipifarnib demonstrates robust and durable activity as a monotherapy in advanced AITL, an aggressive form of T-cell lymphoma – – Enhanced activity (40% CR rate, 70% ORR).

  • GlobeNewswire

    Kura Oncology to Participate in Piper Jaffray Healthcare Conference

    SAN DIEGO, Nov. 26, 2019 -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the.

  • Thomson Reuters StreetEvents

    Edited Transcript of KURA earnings conference call or presentation 5-Nov-19 9:30pm GMT

    Q3 2019 Kura Oncology Inc Earnings Call

  • GlobeNewswire

    Kura Oncology to Present at Stifel Healthcare Conference

    SAN DIEGO, Nov. 12, 2019 -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the.

  • GlobeNewswire

    Kura Oncology Announces Upcoming Presentation at ASH Annual Meeting

    SAN DIEGO, Nov. 06, 2019 -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment.